Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

NCT05650723 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Zanubrutinib Pill
DRUG: Venetoclax Pill
DRUG: Obinutuzumab Injection

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]
[object Object]